XXXX : a single-center experience.

@entity1 @entity646 @entity1071 @entity409 @entity16900 @entity74 @entity2834 @entity209 @entity157
OBJECTIVE: We performed single-center outcome comparison of pediatric recipients who underwent liver transplantation for either @entity74 including the clinical impact of using heterozygote parents as living donors. MATERIALS AND METHODS: Pediatric liver transplant recipients from September 2007 to December 2010 were included. @entity1 were separated into 2 categories by etiology of @entity409 : (1) genetic or metabolic @entity409 (G/M) and (2) nongenetic or metabolic @entity409 (non-G/M), which included all other remaining etiologies combined. @entity1 demographics, recipient and donor characteristics, graft type, operative data, recipient complications, allograft and @entity1 survival were analyzed. RESULTS: Forty liver transplants were performed on 40 @entity1 ; 18 were transplanted for G/M; mean waiting time was 101 days for G/M group and 57 days for non-G/M group; 9 @entity1 were listed as status 1, 5 were granted @entity16900 /MELD exceptions; the overall mean @entity16900 /MELD score was 21. Four G/M @entity1 had @entity157 in the explant without microvascular invasion. Overall complications requiring either surgery or interventional radiology occurred in 14 @entity1 -G/M (n = 5); @entity2834 @entity646 was seen in 11 @entity1 (G/M, n = 1); detectable EBV DNA was detectable in 8 @entity1 (G/M, n = 4), acute cellular rejection was seen in 10 (G/M, n = 5), postransplant @entity1071 occurred in 2 G/M @entity1 ; and 1 G/M @entity1 showed significantly improved posttransplant neurologic motor function. @entity1 with G/M who received a living donor liver transplant from heterozygote parents did well without any signs of expressing underlying @entity209 . Posttransplant graft and @entity1 overall survival at 12 months for G/M and non-G/M was 100%, and at 36 months, 83% and 100%, respectively. CONCLUSION: The majority of @entity1 transplanted for either @entity74 were status 1 or awarded UNOS exception points. Cadaveric split livers and live donors including obligate heterozygotes resulted in excellent allograft and @entity1 survival outcomes. In metabolic and genetic @entity409 , close follow-up and timely transplantation can preclude malignant spread and prevent disease progression and consequences, as well as reverse neurologic sequelae.
